Wally Klemp, with Moleculin Biotech, Inc. (MBRX), discusses on Uptick Network their new treatment for Second-Line Leukemia Patients

Jasyn Blair interviews Wally Klemp, CEO of Moleculin Biotech Inc. (NASDAQ:MBRX) and they discuss their new treatment for Second-Line Leukemia Patients.


We are pleased to share the following UPTICK Network Stock Day Radio Show and Podcast content. The CEOs interviewed on Stock Day did not incur any charges for their time with Uptick CEO Everett Jolly. Uptick staff is always looking for exciting companies to bring to our interested readers and listeners. Contact us at (602) 441-3474 if you would like further information on the UPTICK Network or Uptick services.

Leave a Reply

Close Menu